Gelonghui, March 18 | Jilin Aodong (000623.SZ) announced that the company held the 8th meeting of the 11th board of directors and the 7th meeting of the 11th board of supervisors to review and pass the “Bill on Foreign Investment” on March 18, 2024. According to the company's development strategy plan, the company and its holding subsidiary Jilin Aodong Yanbian Pharmaceutical Co., Ltd. (“Yanbian Pharmaceutical”) jointly invested 300 million yuan to establish a subsidiary, Aodong Pharmaceutical (Anhui) Co., Ltd. (tentative name, subject to local industrial and commercial approval, referred to as “Aodong Anhui Company” for short) Investment 3 million yuan, accounting for 1.00% of the registered capital of Aodong Anhui Company; Yanbian Pharmaceutical invested 297 million yuan, accounting for 99.00% of the registered capital of Aodong Anhui Company. Aodong Anhui Company is mainly engaged in research and development, production, storage, sales and extension services of modern traditional Chinese medicine (proprietary Chinese medicine, Chinese medicine tablets, traditional Chinese medicine formula granules) (the specific business scope is subject to industrial and commercial registration).